Gloucester Pharmaceuticals Announces Presentation of Romidepsin Data at 2007 American...

Gloucester Pharmaceuticals Announces Presentation of Romidepsin Data at 2007 American Society of Hematology (ASH) Annual MeetingCAMBRIDGE, Mass.--(Business Wire)--Gloucester Pharmaceuticals, Inc., an oncology focusedbiopharmaceutical company, announced today that two abstractsdetailing results from clinical trials of the Company's lead productcandidate, romidepsin, will be presented at the 2007 American Societyof Hematology's 49th Annual Meeting, to be held December 8-11 inAtlanta, Georgia. Dr. Miles Prince, Chair of Clinical Cancer Services at the PeterMacCallum Cancer Centre, will present Abstract #1167 "Safety andEfficacy of the Combination of Bortezomib with the Histone DeacetylaseInhibitor Romidepsin in Patients with Relapsed and Refractory MultipleMyeloma: Preliminary Results of a Phase I Trial" in a poster sessionon Saturday, December 8, 2007. Dr. Youn H. Kim, of the Stanford Comprehensive Cancer Center, willpresent Abstract #123 "Romidepsin (depsipeptide) Induces ClinicallySignificant Responses in Treatment-Refractory CTCL: An International,Multicenter Study" in an oral session on Sunday, December 9, 2007. Copies of these abstracts are now available and can be viewedon-line through the ASH website: www.hematology.org. About Romidepsin Romidepsin is a novel agent in a new class of anti-cancer drugsknown as histone deacetylase inhibitors. The Company is conducting apivotal phase II study of romidepsin for patients with cutaneousT-cell lymphoma (CTCL) and has initiated a pivotal phase II study forpatients with peripheral T-cell lymphoma (PTCL). Romidepsin hasreceived Orphan Drug Designation from the Food and Drug Administration

(FDA) for the treatment of non-Hodgkin T-cell lymphomas, whichincludes CTCL and PTCL. In addition, the European Agency for theEvaluation of Medicinal Products (EMEA) has issued Orphan Drug statusfor the treatment of both CTCL and PTCL. Fast Track status for CTCLand PTCL has also been designated by the FDA. Romidepsin is inclinical trials for a variety of other hematological malignancies andsolid tumors, including hormone refractory prostate cancer, pancreaticcancer and multiple myeloma. These trials and others are beingconducted by the Company or the National Cancer Institute (NCI) undera Cooperative Research and Development Agreement (CRADA) with theCompany. About Gloucester Pharmaceuticals, Inc. Gloucester Pharmaceuticals, Inc. is a privately-held,venture-backed company that develops and commercializes innovativeproducts for the treatment of cancer patients. Gloucester isheadquartered in Cambridge, MA. For more information on Gloucester andour clinical development program visit our website atwww.gloucesterpharma.com or call 888-474-2825.MediaKMorrisPRKathryn Morris, 845-635-9828kathryn@kmorrispr.comorGloucester PharmaceuticalsBeverly Holley, 617-583-1362beverly.holley@gloucesterpharma.comCopyright Business Wire 2007